Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study
| Autor: | Yun Jung Choi, Hyonggin An, Young Suk Park, Jin-Hee Ahn, Yeul Hong Kim, Ho Yeong Lim, Kyong Hwa Park, Sang Hee Lim, Jeeyun Lee, Yu Jung Kim, Mi Sun Yun, Dong-Churl Suh |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology Leiomyosarcoma Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty Adolescent Docetaxel Neutropenia Deoxycytidine Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Off-label use Adverse effect Aged Retrospective Studies Univariate analysis business.industry Soft tissue sarcoma Hazard ratio Sarcoma Retrospective cohort study Advanced soft tissue sarcoma Middle Aged medicine.disease Gemcitabine Retrospective study 030104 developmental biology 030220 oncology & carcinogenesis Female Taxoids Original Article business medicine.drug |
| Zdroj: | Cancer Research and Treatment : Official Journal of Korean Cancer Association |
| ISSN: | 2005-9256 1598-2998 |
| Popis: | Purpose This nationwide retrospective study was conducted to evaluate the efficacy and safety of combined gemcitabine and docetaxel (GD) as an off-label therapy for advanced soft tissue sarcoma, which has limited treatment options owing to its rare occurrence. Materials and Methods A total of 228 patients received GD therapy for advanced soft tissue sarcoma from 2009 to 2014 in Korea. We retrospectively reviewed the clinical medical records and claims data of these patients. Results A total of 218 patients in 20 medical centers were included in the final analysis (median age, 50.0 years). The objective response rate was 15.1% (34/218, in the leiomyosarcoma subgroup; 26.3%). The median overall survival and progression-free survival were 10.3 months (95% confidence interval [CI], 8.4 to 12.2) and 3.3 months (95% CI, 2.8 to 4.7), respectively. The treatment was discontinued in 7.8% of patients owing to adverse events; however, there was no adverse event-related death. Neutropenia (35.7%) and anemia (15.1%) were the most frequent grade 3/4 toxicities. Univariate analysis for identifying the predictors of the progression-free survival period revealed that patients aged ≤ 50 years had a hazard ratio of 1.388 (95% CI, 1.027 to 1.875; p < 0.05) relative to those aged > 50 years, and the group with leiomyosarcoma had a hazard ratio of 0.693 (95% CI, 0.493 to 0.975; p < 0.05) relative to the group with other histopathological subtypes. Conclusion GD therapy was tolerable and effective for Korean patients with soft tissue sarcoma. In conclusion, for patients with advanced soft tissue sarcoma, especially leiomyosarcoma, GD therapy could be an important therapeutic option. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|